Fifteen-year survival and conditional survival of women with breast cancer in Osaka, Japan: A population-based study

被引:5
作者
Kato, Mizuki [1 ]
Nakata, Kayo [1 ]
Morishima, Toshitaka [1 ]
Kuwabara, Yoshihiro [1 ]
Fujisawa, Fumie [2 ]
Kittaka, Nobuyoshi [3 ]
Nakayama, Takahiro [4 ]
Miyashiro, Isao [1 ]
机构
[1] Osaka Int Canc Inst, Canc Control Ctr, Osaka, Japan
[2] Osaka Int Canc Inst, Dept Med Oncol, Osaka, Japan
[3] Osaka Rosai Hosp, Dept Breast Surg, Osaka, Japan
[4] Osaka Int Canc Inst, Dept Breast & Endocrine Surg, Osaka, Japan
关键词
breast cancer; epidemiology; survival; women's cancer; AGE; TRENDS; RECURRENCE; FEATURES;
D O I
10.1002/cam4.6016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background In recent years, the survival of patients with breast cancer has improved. However, few published studies have a longer than 10-year follow-up. Conditional relative survival (CRS), which is relative survival (RS) of patients who have survived beyond a certain period after diagnosis, is useful for assessing excess mortality among long-term survivors compared with the general population.Methods This was a retrospective observational cohort study. Population-based cancer registry data in Osaka, Japan were used to determine 15-year RS and 5-year CRS of women with breast cancer diagnosed between 2001 and 2002 and followed up for at least 15 years. Fifteen-year RS and age-standardized RS (ASR) were calculated by Ederer II and cohort methods. Five-year CRS according to age group and extent of disease (localized, regional, and distant) was estimated for every year from diagnosis to 10 years.Results In the cohort of 4006 patients, the ASR declined progressively, the 5-year ASR being 85.8%, 10-year ASR 77.3%, and 15-year ASR 71.6%. The overall 5-year CRS exceeded 90% at 5 years after diagnosis, reflecting a small excess mortality compared with the general population. The 5-year CRS of patients with regional and distant disease did not reach 90% within 10 years of follow-up (89.4% for regional and 72.9% for distant disease 10 years after diagnosis), indicating that these patients had substantial excess mortality.Conclusion Long-term survival data can help cancer survivors plan their lives and receive better medical care and support.
引用
收藏
页码:13774 / 13783
页数:10
相关论文
共 42 条
[1]   Neoadjuvant therapy in breast cancer: Can we define its role? [J].
Aapro, MS .
ONCOLOGIST, 2001, 6 :36-39
[2]   Conditional relative survival among long-term survivors of adolescent and young adult cancers [J].
Anderson, Chelsea ;
Smitherman, Andrew B. ;
Nichols, Hazel B. .
CANCER, 2018, 124 (14) :3037-3043
[3]  
[Anonymous], 2020, The global cancer observatory
[4]  
Arias Elizabeth, 2004, Natl Vital Stat Rep, V52, P1
[5]   Time trends in population-based breast cancer survival in Estonia: Analysis by age and stage [J].
Baburin, Aleksei ;
Aareleid, Tiiu ;
Padrik, Peeter ;
Valvere, Vahur ;
Innos, Kaire .
ACTA ONCOLOGICA, 2014, 53 (02) :226-234
[6]  
Bray F., 2021, Cancer incidence in five continents volume XI
[7]  
Bureau of Statistics M. O. I. A. A. C, 2021, STAT FOR RES FORM ST
[8]   Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update [J].
Burstein, Harold J. ;
Lacchetti, Christina ;
Anderson, Holly ;
Buchholz, Thomas A. ;
Davidson, Nancy E. ;
Gelmon, Karen A. ;
Giordano, Sharon H. ;
Hudis, Clifford A. ;
Solky, Alexander J. ;
Stearns, Vered ;
Winer, Eric P. ;
Griggs, Jennifer J. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) :423-+
[9]   Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge [J].
Bushnell, Grace G. ;
Deshmukh, Abhijeet P. ;
den Hollander, Petra ;
Luo, Ming ;
Soundararajan, Rama ;
Jia, Dongya ;
Levine, Herbert ;
Mani, Sendurai A. ;
Wicha, Max S. .
NPJ BREAST CANCER, 2021, 7 (01)
[10]   Hazard of Recurrence among Women after Primary Breast Cancer Treatment-A 10-Year Follow-up Using Data from SEER-Medicare [J].
Cheng, Lee ;
Swartz, Michael D. ;
Zhao, Hui ;
Kapadia, Asha S. ;
Lai, Dejian ;
Rowan, Paul J. ;
Buchholz, Thomas A. ;
Giordano, Sharon H. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (05) :800-809